<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2017-13-2-256-262</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-1454</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>STATINS AND THEIR INTERACTION WITH MODEL CELL MEMBRANES ACCORDING TO THE DATA OF NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY</article-title><trans-title-group xml:lang="ru"><trans-title>СТАТИНЫ И ИХ ВЗАИМОДЕЙСТВИЕ С МОДЕЛЬНЫМИ КЛЕТОЧНЫМИ МЕМБРАНАМИ ПО ДАННЫМ СПЕКТРОСКОПИИ ЯДЕРНОГО МАГНИТНОГО РЕЗОНАНСА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Латфуллин</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Latfullin</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Латфуллин Ильдус Анварович – доктор медицинских наук, профессор кафедры медицинской физики института физики </p><p>420008, Казань, Кремлевская, 18</p></bio><bio xml:lang="en"><p>Ildus A. Latfullin – MD, PhD, Professor, Chair of Medical Physics, Institute of Physics </p><p>Kremlevskaya ul. 18,Kazan, 420008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галиуллина</surname><given-names>Л. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Galiullina</surname><given-names>L. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галиуллина Лейсан Фаритовна – кандидат физико-математических наук, доцент кафедры медицинской физики института физики  </p><p>420008, Казань, Кремлевская, 18</p></bio><bio xml:lang="en"><p>Leisan F. Galiullina - PhD (in Physics and Mathematics), Associate Professor, Chair of Medical Physics, Institute of Physics</p><p>Kremlevskaya ul. 18,Kazan, 420008</p></bio><email xlink:type="simple">lgaliull@kpfu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мусабирова</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Musabirova</surname><given-names>G. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мусабирова Гузель Салаватовна – магистр кафедры медицинской физики института физики </p><p>420008, Казань, Кремлевская, 18</p></bio><bio xml:lang="en"><p>Guzel S. Musabirova – Master, Chair of Medical Physics, Institute of Physics</p><p>Kremlevskaya ul. 18,Kazan, 420008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аганова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Aganova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аганова Оксана Вартановна - аспирант кафедры медицинской физики института физики </p><p>420008, Казань, Кремлевская, 18</p></bio><bio xml:lang="en"><p>Oksana V. Aganova – Fellow, Chair of Medical Physics, Institute of Physics</p><p>Kremlevskaya ul. 18,Kazan, 420008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ким</surname><given-names>З. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>Z. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ким Зульфия Фаритовна – кандидат медицинских наук, доцент кафедры внутренних болезней </p><p>420008, Казань, Кремлевская, 18</p></bio><bio xml:lang="en"><p>Zulfiya F. Kim – MD, PhD, Associate Professor, Chair of Internal Diseases</p><p>Kremlevskaya ul. 18,Kazan, 420008</p><p> </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аганов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Aganov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аганов Альберт Вартанович – доктор химических наук, зав. кафедрой медицинской физики института физики </p><p>420008, Казань, Кремлевская, 18</p></bio><bio xml:lang="en"><p>Albert V. Aganov – PhD (in Chemistry), Head of Chair of Medical Physics, Institute of Physics</p><p>Kremlevskaya ul. 18,Kazan, 420008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клочков</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Klochkov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клочков Владимир Васильевич – доктор химических наук, профессор кафедры медицинской физики института физики </p><p>420008, Казань, Кремлевская, 18</p></bio><bio xml:lang="en"><p>Vladimir V. Klochkov – PhD (in Chemistry), Professor, Chair of Medical Physics, Institute of Physics </p><p>Kremlevskaya ul. 18,Kazan, 420008</p><p> </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Казанский (Приволжский) Федеральный Университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan (Volga Region) Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>04</day><month>05</month><year>2017</year></pub-date><volume>13</volume><issue>2</issue><fpage>256</fpage><lpage>262</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Latfullin I.A., Galiullina L.F., Musabirova G.S., Aganova O.V., Kim Z.F., Aganov A.V., Klochkov V.V., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Латфуллин И.А., Галиуллина Л.Ф., Мусабирова Г.С., Аганова О.А., Ким З.Ф., Аганов А.В., Клочков В.В.</copyright-holder><copyright-holder xml:lang="en">Latfullin I.A., Galiullina L.F., Musabirova G.S., Aganova O.V., Kim Z.F., Aganov A.V., Klochkov V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/1454">https://www.rpcardio.online/jour/article/view/1454</self-uri><abstract><p>Aim. To study the location of pravastatin, simvastatin, fluvastatin and cerivastatin in molecular complexes with model cell membranes based on dodecylphosphocholine, and also to calculate the average interatomic distances between the atoms of statins and micelles. Material and methods. Nuclear magnetic resonance (NMR) spectroscopy was chosen as a method of study. NMR spectroscopy of the Overhauser nuclear effect (NOESY) is one of the most effective methods in the study of intermolecular interactions, in particular, in studies of drugs. Information on the spatial structure of the molecular complex, as well as on the fragments of molecules responsible for the effective interaction leading to complex formation, was obtained by NOESY spectroscopy. All NMR experiments were performed on a Bruker Avance II 500 spectrometer with a 5 mm zgradient inverse sensor with the TOPSPIN software. The calculation of the interatomic distances was made with an accuracy of 0.1 A. Results. The location of pravastatin, simvastatin, fluvastatin and cerivastatin in molecular complexes with model cell membranes based on dodecylphosphocholine was determined based on NMR NOESY experiments. The average interatomic distances between the atoms of statins and micelles were also calculated. Pravastatin weakly binds to the polar surface of the model membrane, while simvastatin penetrates into the space between the hydrocarbon chains of the micelle. Fluvastatin interacts mainly with model membranes by penetration of its aromatic fragments into the surface of the micelle. Cerivastatin has a unique arrangement in the model membrane. It is located deep in the hydrophobic nucleus of the micelle close to the terminal methylene group. Conclusion: Even minor differences in the chemical structure of statins lead to different patterns of interaction with model membranes. These differences can explain the characteristics of the pharmacological properties of these substances.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Изучить расположение правастатина, симвастатина, флувастатина и церивастатина в молекулярных комплексах с модельными клеточными мембранами на основе додецилфосфохолина, а также рассчитать средние межатомные расстояния между атомами статинов и мицелл. Материал и методы. В качестве метода исследования была выбрана спектроскопия ядерного магнитного резонанса (ЯМР). ЯМР спектроскопия ядерного эффекта Оверхаузера (NOESY) является одним из самых эффективных методов в изучении межмолекулярных взаимодействий, в частности, при исследованиях лекарственных препаратов. С помощью NOESY спектроскопии можно получить информацию о пространственной структуре молекулярного комплекса, а также о фрагментах молекул, ответственных за эффективное взаимодействие, приводящее к образованию комплекса. Все ЯМР эксперименты были выполнены на спектрометре Bruker Avance II 500, оборудованном 5 мм z-градиентным инверсным датчиком с программным обеспечением TOPSPIN. Расчет межатомных расстояний проводился с точностью до 0,1 A. Результаты. На основании ЯМР NOESY экспериментов было определено расположение правастатина, симвастатина, флувастатина и церивастатина в молекулярных комплексах с модельными клеточными мембранами на основе додецилфосфохолина, а также рассчитаны средние межатомные расстояния между атомами статинов и мицелл. Правастатин слабо связывается с полярной поверхностью модельной мембраны, в то время как симвастатин проникает в пространство между углеводородными цепями мицеллы. Флувастатин взаимодействует, главным образом, с модельными мембранами путем проникновения его ароматических фрагментов в поверхность мицеллы. Церивастатин имеет уникальное расположение в модельной мембране. Он расположен глубоко в гидрофобном ядре мицеллы близко к концевой метиленовой группе. Заключение. Показано, что даже незначительные различия в химической структуре статинов приводят к различным характерам их взаимодействия с модельными мембранами. Эти различия могут объяснить особенности фармакологических свойств этих соединений.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ядерный магнитный резонанс</kwd><kwd>молекулярный комплекс</kwd><kwd>додецилфосфохолин</kwd><kwd>мицеллы</kwd><kwd>статины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nuclear magnetic resonance</kwd><kwd>molecular complex</kwd><kwd>dodecylphosphocholine</kwd><kwd>micelles</kwd><kwd>statins</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vaughan C.J., Gotto A.M. Jr., Basson C.T. The evolving role of statins in the management of atherosclerosis. Journal of the American College of Cardiology. 2000;35:1-10.</mixed-citation><mixed-citation xml:lang="en">Vaughan C.J., Gotto A.M. Jr., Basson C.T. The evolving role of statins in the management of atherosclerosis. Journal of the American College of Cardiology. 2000;35:1-10.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology &amp; Therapeutics. 1999;84:413-28.</mixed-citation><mixed-citation xml:lang="en">Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology &amp; Therapeutics. 1999;84:413-28.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson P.D., Panza G., Zaleski A., Taylor B. Statin-Associated Side Effects. Journal of the American College of Cardiology. 2016;67(20):2395-410.</mixed-citation><mixed-citation xml:lang="en">Thompson P.D., Panza G., Zaleski A., Taylor B. Statin-Associated Side Effects. Journal of the American College of Cardiology. 2016;67(20):2395-410.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y.Y., Zhu G.Q., Wang Y., et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget. 2016;7(16):21753-62.</mixed-citation><mixed-citation xml:lang="en">Zhou Y.Y., Zhu G.Q., Wang Y., et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget. 2016;7(16):21753-62.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chong P.H., Seeger J.D., Franklin C. Clinically Relevant Differences between the Statins: Implications for Therapeutic Selection. The American Journal of Medicine. 2001;111:390-400.</mixed-citation><mixed-citation xml:lang="en">Chong P.H., Seeger J.D., Franklin C. Clinically Relevant Differences between the Statins: Implications for Therapeutic Selection. The American Journal of Medicine. 2001;111:390-400.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mason R.P., Walter M.F., Day Ch.A., Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. The American Journal of Cardiology. 2005;96:11-23.</mixed-citation><mixed-citation xml:lang="en">Mason R.P., Walter M.F., Day Ch.A., Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. The American Journal of Cardiology. 2005;96:11-23.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Larocque G., Arnold A.A., Chartrand E., et al. Effect of sodium bicarbonate as a pharmaceutical formulation excipient on the interaction of fluvastatin with membrane phospholipids. European Biophysics Journal 2010;39:1637-47.</mixed-citation><mixed-citation xml:lang="en">Larocque G., Arnold A.A., Chartrand E., et al. Effect of sodium bicarbonate as a pharmaceutical formulation excipient on the interaction of fluvastatin with membrane phospholipids. European Biophysics Journal 2010;39:1637-47.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mason R.P. Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins. The American Journal of Cardiology. 2006;98:34P-41P.</mixed-citation><mixed-citation xml:lang="en">Mason R.P. Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins. The American Journal of Cardiology. 2006;98:34P-41P.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rakhmatullin I.Z., Galiullina L.F., Klochkova E.A., et al. Structural studies of pravastatin and simvastatin and their complexes with SDS micelles by NMR spectroscopy. Journal of Molecular Structure. 2016; 1105: 25-9.</mixed-citation><mixed-citation xml:lang="en">Rakhmatullin I.Z., Galiullina L.F., Klochkova E.A., et al. Structural studies of pravastatin and simvastatin and their complexes with SDS micelles by NMR spectroscopy. Journal of Molecular Structure. 2016; 1105: 25-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Latfullin I.A., Galiullina L.F., Rakhmatullin I.Z., et al. Pleiotropic statins. Are there any possibilities for explaining the phenomenon? Rational Pharmacotherapy in Cardiology. 2015;11(6):634-7. (In Russ.) [Латфуллин И.А., Галиуллина Л.Ф., Рахматуллин И.З., и др. Плейотропность статинов. Имеются ли возможности объяснения феномена? Рациональная Фармакотерапия в Кардиологии. 2015;11(6):634-7].</mixed-citation><mixed-citation xml:lang="en">Latfullin I.A., Galiullina L.F., Rakhmatullin I.Z., et al. Pleiotropic statins. Are there any possibilities for explaining the phenomenon? Rational Pharmacotherapy in Cardiology. 2015;11(6):634-7. (In Russ.) [Латфуллин И.А., Галиуллина Л.Ф., Рахматуллин И.З., и др. Плейотропность статинов. Имеются ли возможности объяснения феномена? Рациональная Фармакотерапия в Кардиологии. 2015;11(6):634-7].</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Galiullina L.F., Rakhmatullin I.Z., Klochkova E.A., et al. Structure of pravastatin and its complex with sodium dodecyl sulfate micelles studied by NMR spectroscopy. Magnetic Resonance in Chemistry. 2015;53(2):110-4.</mixed-citation><mixed-citation xml:lang="en">Galiullina L.F., Rakhmatullin I.Z., Klochkova E.A., et al. Structure of pravastatin and its complex with sodium dodecyl sulfate micelles studied by NMR spectroscopy. Magnetic Resonance in Chemistry. 2015;53(2):110-4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Galiullina L.F., Aganova O.V., Latfullin I.A., et al. NMR Study of conformational structure of fluvastatin and its complex with dodecylphosphocholine micelles. Bionanoscience. 2016;6:352-4.</mixed-citation><mixed-citation xml:lang="en">Galiullina L.F., Aganova O.V., Latfullin I.A., et al. NMR Study of conformational structure of fluvastatin and its complex with dodecylphosphocholine micelles. Bionanoscience. 2016;6:352-4.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Galiullina L.F., Aganova O.V., Latfullin I.A., et al. Interaction of different statins with model membranes by NMR data. BBA Biomembranes. 2017;1859:295-300.</mixed-citation><mixed-citation xml:lang="en">Galiullina L.F., Aganova O.V., Latfullin I.A., et al. Interaction of different statins with model membranes by NMR data. BBA Biomembranes. 2017;1859:295-300.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wagner R., Berger S. Gradient-selected NOESY - A fourfold reduction of the measurement time for the NOESY experiment. Journal of Magnetic Resonance, Series A. 1996;123:119-21.</mixed-citation><mixed-citation xml:lang="en">Wagner R., Berger S. Gradient-selected NOESY - A fourfold reduction of the measurement time for the NOESY experiment. Journal of Magnetic Resonance, Series A. 1996;123:119-21.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stott K., Stonehouse J., Keeler J. et al. Excitation sculpting in high-resolution nuclear magnetic resonance spectroscopy: application to selective NOE experiments. Journal of the American Chemical Society. 1995;117:4199-200.</mixed-citation><mixed-citation xml:lang="en">Stott K., Stonehouse J., Keeler J. et al. Excitation sculpting in high-resolution nuclear magnetic resonance spectroscopy: application to selective NOE experiments. Journal of the American Chemical Society. 1995;117:4199-200.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kessler H., Gehrke M., Grisenger C. Two-dimensional NMR spectroscopy: background and overview experiments. Angewandte Chemie International Edition. 1988;27(4):490-536.</mixed-citation><mixed-citation xml:lang="en">Kessler H., Gehrke M., Grisenger C. Two-dimensional NMR spectroscopy: background and overview experiments. Angewandte Chemie International Edition. 1988;27(4):490-536.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Furberg C.D. Natural statins and stroke risk. Circulation. 1999;99:185-8.</mixed-citation><mixed-citation xml:lang="en">Furberg C.D. Natural statins and stroke risk. Circulation. 1999;99:185-8.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovascular Drugs and Therapy. 2003;17:265-85.</mixed-citation><mixed-citation xml:lang="en">Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovascular Drugs and Therapy. 2003;17:265-85.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109:III50-7.</mixed-citation><mixed-citation xml:lang="en">Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109:III50-7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Davidson M.H. Comparative effects of lipid-lowering therapies. Progress in Cardiovascular Diseases. 2004;47:73-104.</mixed-citation><mixed-citation xml:lang="en">Davidson M.H. Comparative effects of lipid-lowering therapies. Progress in Cardiovascular Diseases. 2004;47:73-104.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lindahl A., Sandstrom R., Ungell A.-L., Abrahamsson B., Knutson T.W., Knutson L., Lennerna H. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clinical Pharmacology &amp; Therapeutics. 1996;60:493-503.</mixed-citation><mixed-citation xml:lang="en">Lindahl A., Sandstrom R., Ungell A.-L., Abrahamsson B., Knutson T.W., Knutson L., Lennerna H. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clinical Pharmacology &amp; Therapeutics. 1996;60:493-503.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
